Delving into the Latest Updates on BP-2201 with Synapse

Overview

Basic Info

Drug Type

CAR-T

Synonyms

iPS-NKT - BrightPath Biotherapeutics

Target-

Mechanism

Immunologic cytotoxicity, Natural killer cell replacements

Therapeutic Areas

Neoplasms

Active Indication

Squamous Cell Carcinoma of Head and Neck

Inactive Indication-

Originator Organization

Riken Corp.

Active Organization

BrightPath Biotherapeutics Co., Ltd.

Inactive Organization

Riken Corp.

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

AbstractAimsThis study aimed to investigate the probiotic effects of Acetobacter pasteurianus BP2201, isolated from brewing mass, for the treatment of alcohol-induced learning and memory ability impairments in a Caenorhabditis elegans model.Methods and resultsAcetobacter pasteurianus BP2201 was examined for probiotic properties, including acid and bile salt resistance, ethanol degradation, antioxidant efficacy, hemolytic activity, and susceptibility to antibiotics. The strain displayed robust acid and bile salt tolerance, efficient ethanol degradation, potent antioxidant activity, and susceptibility to specific antibiotics. Additionally, in the C. elegans model, administering A. pasteurianus BP2201 significantly improved alcohol-induced learning and memory impairments.ConclusionsAcetobacter pasteurianus BP2201 proves to be a promising candidate strain for the treatment of learning and memory impairments induced by alcohol intake.

100 Deals associated with BP-2201

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Head and Neck Neoplasms	Phase 2	JP	BrightPath Biotherapeutics Co., Ltd.	09 Jun 2020
Squamous Cell Carcinoma of Head and Neck	Phase 1	-	BrightPath Biotherapeutics Co., Ltd.	-